BioSpace News Archive

Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced that it intends to offer and sell shares of its common stock and Series 1 convertible preferred stock in two concurrent but separate underwritten public offerings (together, the “Offerings”). The Offerings are subject to market and other conditions, and the

New analysis of age-related macular degeneration (AMD) progression in Phase 2 FILLY study accepted as late-breaking oral presentation at European Society of Retina Specialists Congress (EURETINA) Pegcetacoplan targets C3, and has the potential to control the irreversible lesion growth in GA, an advanced form of AMD and leading cause of blindness WALTHAM, Mass., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in

Evolent Health (NYSE: EVH), a health care company that delivers proven clinical and administrative solutions to payers and providers, today announced it will host its annual Investor and Analyst Day on Tuesday, September 29, 2020 , from 10:00 a.m. ET to 12:30 p.m. ET . This year’s event will be held virtually. To register for

Complete view of the customer enables field teams to drive relevant, timely, and compliant engagement across all channels

This Prostate Cancer Awareness Month Prostate Oncology Specialists urges men to be mindful of what they’re consuming.

Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment of serious chronic diseases, today announced two presentations at the Jefferies Next Generation IBD Therapeutics Virtual Summit. Members of the Morphic management team are scheduled to participate in a panel discussion at 8:45 a.m. ET on Wednesday, September 23, 2020, as well as present a company

Immune Regulation Limited (“Immune Regulation”), a US and UK based clinical stage biotechnology company, today announced the closing of a Series B funding round led by Boston based Morningside Ventures (“Morningside”), alongside existing shareholders including London based 24Haymarket.

Novartis announced today detailed results from the Phase III COMBI-i trial evaluating the investigational immunotherapy spartalizumab (PDR001) in combination with the targeted therapies Tafinlar® (dabrafenib) and Mekinist® (trametinib) compared to Tafinlar + Mekinist alone

Halberd Corporation released a progress update on the research being conducted in conjunction with Arizona State University researchers.

Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical company, announced today that the U.S. Food and Drug Administration (“FDA”) acknowledged receipt of the resubmission, by its US subsidiary, Prometic Biotherapeutics Inc., of the Biologic License Application (“BLA”) for Ryplazim®